Clinical trials: Patients With Diabetes.
Obesity, Type 2 Diabetes Mellitus in Obese
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes
This is a multiple dose study to evaluate the safety, tolerability, PK, and PD of K-757 and K-833 when co-administered in overweight/obese patients with Type 2 diabetes mellitus (T2DM).
- Trial name
- NCT05890950
- Testing
- K-757 and K-833
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- TriGemX Bio, Inc.
Diabetes Mellitus, Type 2
A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (ie, blood levels of JNJ-28431754) and pharmacodynamics (ie, urine and blood levels of glucose) of JNJ-28431754 compared to placebo in patients…
- Trial name
- NCT00963768
- Testing
- JNJ 28431754
- Where
- 3 sites in United States, Germany and 1 more
- Volunteers
- 116 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Type 2 Diabetes Mellitus
Body Weight Effects on Glucophage's Efficacy in Chinese Diagnosed T2DM Patients
The purpose of this study is to investigate the effect of the baseline body mass index (BMI) on the response to Glucophage XR monotherapy in glycemic control in Chinese patients with newly diagnosed type 2 diabetes
- Trial name
- NCT00778622
- Testing
- Metformin XR
- Where
- 14 sites in China
- Volunteers
- 371 people
- Sponsor
- Bristol-Myers Squibb
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
A Study for Patients With Diabetes Mellitus (IOPA)
The purpose of this study is to compare glycemic control (HbA1c) in Chinese patients with type 1 or type 2 diabetes when treated with insulin lispro low mixture and human insulin 30/70.
- Trial name
- IOPA (NCT00420095)
- Testing
- Human insulin 30/70, Insulin lispro low mix
- Where
- 4 sites in China
- Volunteers
- 117 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
Observational Cohort Study Evaluating the Effectiveness of an Education Program (NGAYDAUTIEN) in Combination With Gliclazide MR in the Management of Uncontrolled Type 2 Diabetic Patients.
The primary objective is to assess the change of HbA1c level from baseline after a 6-month follow up among uncontrolled patients with T2D who will be initiated to Diamicron® MR 60 (originator product) plus an educational program…
- Trial name
- EDUDIA (NCT06704802)
- Where
- France
- Volunteers
- 678 people
- Sponsor
- Servier Affaires Médicales
Diabetes Mellitus Type 2, Cardiovascular Diseases
PRimary IndividualiZed Evaluation of Cardiovascular Events in Patients With Diabetes Mellitus Using hemoTAG
To evaluate the proportion of diabetic mellitus patients with CV events as measured by HEMOTAG.
- Conditions
- Diabetes Mellitus Type 2, Cardiovascular Diseases, Coronary Artery Disease, Cerebrovascular Disease
- Trial name
- PRIZETAG (NCT06567795)
- Testing
- Hemotag
- Where
- United States
- Volunteers
- 189 people
- Sponsor
- Aventusoft, LLC.
Diabetes Mellitus, Type 2
Efficacy and Safety of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes and Mild Hyperglycemia
This study is not being conducted in the United States. Key long-term clinical studies have shown that people with type 2 diabetes should try to achieve overall blood glucose levels as close to normal as possible.
- Trial name
- NCT00101712
- Testing
- vildagliptin
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 274 people
- Sponsor
- Novartis Pharmaceuticals
Type1 Diabetes
Multiple Ascending Dose (MAD) Study of IMT-002 in HLA-DQ8-positive Type 1 Diabetes
This study is designed to characterize the safety, steady-state pharmacokinetics (PK) of IMT-002, and will serve as a dose range identification for the pharmacodynamic effect of blocking self-antigen presentation in adults with…
- Trial name
- NCT04625595
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Immunomolecular Therapeutics, Inc.
Type 2 Diabetes Mellitus
A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)
A study to assess the safety and efficacy of the addition of sitagliptin compared to placebo in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on metformin.
- Trial name
- NCT00813995
- Testing
- Comparator: Sitagliptin phosphate
- Volunteers
- 395 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetic Peripheral Neuropathy
Safety and Efficacy of CBX129801 in Patients With Type 1 Diabetes
The purpose of the study is to determine the beneficial effects of CBX129801 (PEGylated synthetic human C-peptide) following weekly subcutaneous administration for 12 months in type 1 diabetes mellitus patients (T1DM) with mild…
- Trial name
- NCT01681290
- Testing
- CBX129801
- Where
- 29 sites in United States, Canada and 1 more
- Volunteers
- 250 people
- Sponsor
- Cebix Incorporated
Diabetes Mellitus Type 2
A Study of Dipeptidyl-peptidase IV (DPP-IV) RO4876904 in Patients With Type 2 Diabetes.
This 5 arm study will assess the efficacy, pharmacokinetics, safety and tolerability of a DPP-IV inhibitor compared to placebo in patients with type 2 diabetes.
- Trial name
- NCT00502710
- Testing
- RO4876904
- Where
- 48 sites in United States, Australia and 7 more
- Volunteers
- 289 people
- Sponsor
- Hoffmann-La Roche
Type 2 Diabetes, Diabetic Cardiomyopathies
IMPROVE-DiCE: Study to Evaluate Effect of IMB-1018972 on Cardiac Energetics in T2DM & Obesity (Pt 1) With HFpEF (Pt 2)
The purpose of this study is to assess the activity of IMB-1018972 on cardiac energetic reserve at rest and during stress and to assess safety and tolerability
- Conditions
- Type 2 Diabetes, Diabetic Cardiomyopathies, HFpEF - Heart Failure With Preserved Ejection Fraction
- Trial name
- NCT04826159
- Testing
- IMB-1018972
- Where
- United Kingdom
- Volunteers
- 49 people
- Sponsor
- Imbria Pharmaceuticals, Inc.
Diabetic Foot Ulcer
Oral BBR-012 in the Treatment of Diabetic Foot Ulcers, Proof of Concept Study
The aim of this Clinical Proof of Principle study is to evaluate the effect of BBR-012 on the healing of complicated diabetic foot ulcers.
- Trial name
- BBR-012 (NCT01342497)
- Testing
- isoniazide
- Where
- 11 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Bridge BioResearch Ltd.
Diabetes Mellitus, Type 2
Superiority of Glimepiride Over Sitagliptin in Naive Type 2 Diabetes Patients
Primary Objective: To determine the superiority of glimepiride over sitagliptin in the reduction of HbA1c after 6 months of treatment in patients with monotherapy until the end of the trial.
- Trial name
- SUMER (NCT00957060)
- Testing
- GLIMEPIRIDE (HOE490), SITAGLIPTIN
- Where
- 2 sites in Guatemala, Mexico
- Volunteers
- 400 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in China
The purpose of the study is to collect information on how Tresiba® works in patients with type 2 diabetes in China. The study will be based on data already recorded in participants' medical records and no new tests or procedures…
- Trial name
- CN-TREAT (NCT04227431)
- Testing
- Insulin degludec
- Where
- 56 sites in China
- Volunteers
- 938 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Bangladesh, Indonesia, Malaysia, Philippines, Sri Lanka and Vietnam
This study is conducted in Asia. The aim of this non-interventional study is to evaluate the current status of diabetes management, control, and complications in diabetic subjects in Vietnam.
- Trial name
- DiabCare Asia (NCT02066766)
- Testing
- No treatment given
- Where
- Vietnam
- Volunteers
- 1,631 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Long-Term Safety Study of Vildagliptin in Patients With Type 2 Diabetes
This study is not being conducted in the United States. Vildagliptin is an oral antidiabetic agent. This 52-week clinical study is designed as an open label, long-term study aimed to evaluate the safety of vildagliptin in…
- Trial name
- NCT00325429
- Testing
- Vildagliptin
- Where
- Japan
- Volunteers
- 150 people
- Sponsor
- Novartis
Diabetes Mellitus
Efficacy of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus
The purpose of this study was to determine the safety and efficacy of TAK-559, once daily (QD), in Type 2 Diabetes subjects.
- Trial name
- NCT00763022
- Testing
- TAK-559
- Volunteers
- 302 people
- Sponsor
- Takeda
Severe Complications of Urinary Tract Infections
Complications of UTI in Patients on Dapagliflozin
The objective of this study is to compare, by insulin use at the index date, the sex-specific incidence of hospitalization or emergency department (ED) visit for severe complications of urinary tract infections (UTI), defined as…
- Trial name
- NCT02695173
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 683,380 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 1
Observational Study on Levemir® in Obese Diabetic Patients
This study is conducted in Europe. The aim of this observational study is to investigate the effect of switch from other basal insulin treatments to Levemir® on body weight in obese diabetic patients.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- KILOS (NCT00849342)
- Testing
- insulin detemir
- Where
- 2 sites in Netherlands, Slovenia
- Volunteers
- 580 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.